About NeoStem, Inc.
NeoStem is managing a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered the research and development and therapeutic arenas, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic- like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.
Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995, including statements concerning the ability of NeoStem, Inc.
("the Company") to develop the adult stem cell business, to develop the
VSEL technology, the future of regenerative medicine and the role of adult
stem cells and VSELs in that future, the future use of adult stem cells and
VSELs as a treatment option and the potential revenue growth of the
Company's business. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking statements. The
Company's ability to enter the adult stem cell arena, its success in such
arena and future operating results are dependent upon many factors,
including but not limited to (i) the Company's
|SOURCE NeoStem, Inc.|
Copyright©2008 PR Newswire.
All rights reserved